Back

Impact of triglyceride deposit cardiomyovasculopathy, a novel type atherosclerosis with triglyceride deposition in coronary arteries, on neointimal proliferation after coronary stent-implantation

25 August 2018 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Poster Session 2 - Coronary interventions: stents Restenosis ESC Premium Access ESC Congress 2018

About the speaker

Photo
Doctor Mayu Suzuki

Aichi medical university hospital, Aichi (Japan)

8 More presentations in this session

Presentation thumbnail
Evolution of periprocedural modifications of oxidative stress and inflammation markers according to the length of implanted stent
Doctor C. Dumanschi (Chisinau, MD)
Abstract
Presentation thumbnail
Association between tissue morphology of in-stent restenosis lesions assessed with optical coherence tomography and late-term results after percutaneous coronary intervention
Doctor T. Tada (Kurashiki, JP)
Abstract
Presentation thumbnail
Evaluation of transradial versus transfemoral procedures in all-comers patients treated with the dual-therapy stent
Doctor D. Kalkman (Amsterdam, NL)
Abstract Slides
Presentation thumbnail
COMBO stent PCI for elderly patients: one year clinical outcomes and DAPT cessation patterns from the global MASCOT registry
Doctor J. Chandrasekhar (Melbourne, AU)
Abstract
Presentation thumbnail
Clinical outcomes by potency of P2Y12 inhibitor following COMBO DTS PCI: From the COMBO collaboration
Doctor J. Chandrasekhar (Melbourne, AU)
Abstract

Access the full session

Session thumbnail
Poster Session 2 - Coronary interventions: stents

The Event

Event poster

ESC Congress 2018

25 August - 29 August 2018
You may be interested in
thumbnail
Congress Presentation
Percutaneous intervention is better than surgery in real life for most patients: pro
thumbnail
Congress Presentation
Intracoronary imaging: from research tool to class IA in the Guidelines
thumbnail
Congress Presentation
Prognostic impact of intravascular imaging in percutaneous coronary intervention according to atherothrombotic risk

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources